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INTEREST OF AMICUS CURIAE1 
Amicus curiae Kaiser Permanente2 is the largest 
private integrated health care delivery system in            
the United States, providing high-quality, affordable 
health care services to approximately 8.9 million 
members in nine states and the District of Columbia. 
Kaiser Permanente consists of three different          
operating entities.  Kaiser Foundation Health Plan, 
Inc.,3 the nation’s largest not-for-profit health plan, 
and its subsidiary plans provide and administer 
health care coverage for their members.  The not-for-
profit Kaiser Foundation Hospitals, which operates 
36 hospitals and over 450 other clinical facilities, 
provides members and other patients with hospital 
services, either directly or through contractual            
arrangements.  And the eight Permanente Medical 
Groups, which are physician-owned, consist of more 

1 Pursuant to Supreme Court Rule 37.6, counsel for amicus 
represents that no counsel for a party authored this brief in 
whole or in part and that none of the parties or their counsel, 
nor any other person or entity other than amicus or its counsel, 
made a monetary contribution intended to fund the preparation 
or submission of this brief.  Pursuant to Rule 37.2(a), counsel            
for amicus represents that all parties were provided notice of 
amicus’s intention to file this brief at least 10 days before its due 
date.  Pursuant to Rule 37.3(a), counsel for amicus represents 
that all parties have consented to the filing of this brief and that 
letters reflecting their consent are on file with the Clerk. 
2 “Kaiser Permanente” is not a legal entity but a registered 
trademark or trade name used by the separate legal entities 
described above.  Unless otherwise indicated, the term “Kaiser 
Permanente” is used throughout this brief to refer collectively to 
those entities.  
3 The Kaiser Foundation health plans are providers of health 
care services as well as health plans, owning and operating             
facilities where outpatient services are provided and employing 
many non-physician providers. 
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than 15,000 primary care physicians, specialists, and 
geneticists who exclusively provide or arrange for all 
types of medical care for Kaiser Foundation Health 
Plan members.  In addition to providing medical        
care, Kaiser Permanente conducts and supports a 
broad agenda of clinical and health services research 
through its various research entities.  Research has 
long been a hallmark of Kaiser Permanente and is one 
of the ways Kaiser Permanente demonstrates its ben-
efits to the communities it serves.  Kaiser Permanente 
conducts research throughout its service areas, both 
within research centers and in medical centers and 
other health care delivery venues. 
Kaiser Permanente has extensive experience with 
issues connected to patient care, research, and health 
care costs.  In particular, and as described more fully 
below, Kaiser Permanente has firsthand experience 
with the negative effects that flow from granting            
patent rights on human genes, including specifically 
the BRCA1 and BRCA2 genes at issue in this case.   
STATEMENT OF THE CASE 
As framed in the petition, this case presents the 
question whether human genes are patentable.   
Petitioners brought this case to challenge the           
validity and constitutionality of seven patents owned 
by respondents Myriad Genetics, Inc. and the Uni-
versity of Utah Research Foundation (collectively, 
“Myriad”).  Three of those patents are the subject of 
the petition.4  The challenged claims of these three 

4 The relevant claims of the three patents still at issue are             
directed to compositions of matter that petitioners argue are 
ineligible for patent protection under 35 U.S.C. § 101.  The         
other four patents were directed to processes; the district court 
and the court of appeals held all but one of the challenged             
method claims in those patents to be ineligible subject matter 
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patents are all directed to isolated molecules of            
deoxyribonucleic acid (“DNA”) corresponding to one 
of two human genes known as BRCA1 and BRCA2.  
These two genes are among the approximately 
25,000 that comprise the human genome found in 
nearly every cell of the human body.  Mutations            
in the DNA sequences of the BRCA1 and BRCA2 
genes are associated with increased risk of breast 
and ovarian cancer.   
Collectively, Myriad’s patents claim both the          
normal (or “wild-type”) versions of the BRCA1 and 
BRCA2 genes and all possible variations and muta-
tions of those genes, known or unknown.  See Pet. 
App. 181a, 307a-308a.  The claims are limited only 
by the requirement that these genes be “isolated” — 
that is, removed from a cell and separated from other 
genetic material.  Isolation of a gene is achieved 
through the application of standard techniques 
known in the scientific and medical communities; 
Myriad claims no intellectual property right in the 
actual methods of isolation.  Instead, Myriad’s pat-
ents claim the human DNA that has been “isolated” 
from its cellular environment by application of those 
methods.  Due to the breadth of its patent claims,          
as noted in the petition, “Myriad claims ownership          
of the BRCA1 and BRCA2 genes of every American.”  
Pet. 8.  The patents have allowed Myriad to establish 
and enforce a monopoly on clinical testing for BRCA1 
and BRCA2 mutations.  Moreover, as the exclusive 
provider of this testing, Myriad has complete control 
over the resulting data that could otherwise be            
used by researchers to advance understanding of the 

under § 101.  See Pet. App. 53a-60a, 224a-236a.  The petition 
does not seek review of the court’s holding that one of the             
method claims is directed to patent-eligible subject matter.  See 
Pet. 7 n.2. 
 4
precise role these genes play in increasing cancer 
risk.  Myriad’s patents entitle it not only to charge a 
licensing fee for this research but also to control who 
may conduct it and under what circumstances.   
The critical question presented by this case is 
whether the kind of monopoly enjoyed by Myriad and 
other gene patent owners is lawful.  Under 35 U.S.C. 
§ 101, an inventor may obtain a patent for “any new 
and useful process, machine, manufacture, or compo-
sition of matter, or any new and useful improvement 
thereof.”  This Court has long interpreted § 101             
to exclude three categories that are outside the          
otherwise “wide scope” of patent-eligible subject            
matter:  “The laws of nature, physical phenomena, 
and abstract ideas have been held not patentable.”  
Diamond v. Chakrabarty, 447 U.S. 303, 308-09 (1980).  
Genes as they exist in the human body, for example, 
are “products of nature” not eligible for patent            
protection.  They are instead “part of the storehouse 
of knowledge of all men . . . [,] free to all men and            
reserved exclusively to none.”  Funk Bros. Seed Co. v. 
Kalo Inoculant Co., 333 U.S. 127, 130 (1948). 
The question raised by Myriad’s patents is whether 
these genes may nonetheless be “reserved exclusive-
ly” to a single owner if they are isolated from their 
native cellular environment.  Under this Court’s           
precedent, the answer turns on whether the isolated 
genes have “markedly different characteristics from 
any found in nature.”  Chakrabarty, 447 U.S. at 310. 
The district court applied that test and concluded 
that isolated DNA is not patentable subject matter 
under § 101.  Granting summary judgment in favor 
of petitioners, the district court emphasized that 
simply isolating DNA from its natural state does not 
change the “fundamental quality of DNA as it exists 
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in the body” — namely, the critical biological infor-
mation contained within the DNA.  Pet. App. 120a.   
Myriad appealed this decision, and a divided panel 
of the court of appeals reversed.  Each member of the 
panel wrote separately.  Judge Lourie, writing for            
the majority, held that an isolated gene is “markedly 
different” from a native gene under Chakrabarty         
because the breaking of covalent chemical bonds 
gives the isolated DNA molecule a “distinctive chem-
ical identity and nature.”  Id. at 45a.  Judge Moore, 
in a separate concurring opinion, agreed that differ-
ences in chemical structure are relevant to patenta-
bility but found it necessary also to analyze “whether 
these differences impart a new utility which makes 
the molecules markedly different from nature.”  Id. 
at 76a (Moore, J., concurring in part).  Judge Moore 
answered this question in the affirmative, concluding 
that isolated DNA has practical applications in            
research and diagnostics for which native DNA is          
unsuitable.  Judge Bryson, dissenting from this part 
of the majority’s ruling, explained of the isolated 
DNA molecules covered by Myriad’s patents that 
“[t]he only material change made to those genes from 
their natural state is the change that is necessarily 
incidental to the extraction of the genes from the            
environment in which they are found in nature.”  Id. 
at 98a (Bryson, J., concurring in part and dissenting 
in part).  He opined that the extraction process alone 
does not render isolated DNA “markedly different” 
from native DNA and specifically rejected the notion 
that there is some “magic to a chemical bond that          
requires us to recognize a new product when a chem-
ical bond is created or broken, but not when other 
atomic or molecular forces are altered.”  Id. at 99a. 
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Petitioners seek review of the panel majority’s 
holding with respect to the patent-eligibility of            
isolated DNA.  Although the petition also asks              
this Court to review other aspects of the appellate 
court’s ruling, including threshold issues related to 
standing, amicus Kaiser Permanente’s interest and 
experience are focused on the substantive question 
whether Myriad’s patent claims and others like them 
are directed to eligible subject matter under 35 
U.S.C. § 101.  
REASONS FOR GRANTING THE WRIT 
The Court should grant the petition for a writ of 
certiorari because the Federal Circuit has decided              
a question of signal importance in patent law that 
should be reviewed by this Court.5  More than 30 
years have passed since this Court last addressed            
the patentability of compositions of matter under            
35 U.S.C. § 101.  The Court has never applied that 
statute to determine whether human genetic mate-
rial may be patented. 
That question is of paramount importance to the 
medical and scientific communities.  As discussed in 
more detail below, Kaiser Permanente’s experience 
with the Myriad patents at issue in this case demon-
strates the significant negative effects on patient 
care, diagnostic expertise, genetic research, and            
medical decisionmaking that flow from granting a 
patent monopoly on human genes.  These negative 
effects will persist (and likely increase) under the            

5 As set forth in the petition, this case also merits this Court’s 
review because the court of appeals misapplied this Court’s            
jurisprudence interpreting § 101.  See Pet. 25-30.  In this brief, 
however, amicus Kaiser Permanente will focus on the reasons 
why gene patentability is an important question of federal law 
that this Court should decide.   
 7
ruling of the court of appeals.  The correctness of            
that ruling is a question that merits consideration by 
this Court. 
I. PATENTS ON ISOLATED DNA DELAY IM-
PROVEMENTS TO CLINICAL CARE AND 
IMPEDE CRITICAL GENETIC RESEARCH 
Advocates of gene patents — including several 
amici that supported Myriad in the court of appeals 
— frequently argue that continued innovation in            
the field of genetics depends on the availability of 
these patents.  They cite the investment required to 
support cutting-edge genetic research and claim that, 
but for the prospect of patent exclusivity and the 
profits it entails, funding would not be forthcoming 
and research would stall.  But Kaiser Permanente’s 
experience with the Myriad patents teaches that the 
opposite is true:  granting patent rights in isolated 
human genes inhibits both clinical treatment and 
scientific research and understanding.    
Myriad’s monopoly on the BRCA1 and BRCA2 
genes extends not only to the actual clinical testing 
for mutations in those genes but also to the use of            
the data compiled from test results.  As the district 
court found, Myriad is the sole provider of BRCA1 
and BRCA2 tests in the United States.  See Pet.            
App. 129a.  Health care providers such as Kaiser 
Permanente must rely exclusively on Myriad to test 
patients’ DNA samples for BRCA1 and BRCA2 muta-
tions.  Myriad maintains a proprietary database con-
taining the results of all of these tests — a valuable 
store of information about known malignant variants 
in the genes as well as variants whose effects             
are currently unknown.  If this information were 
available to doctors and genetic counselors, it would           
enhance medical decisionmaking because these pro-
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viders could more easily place an individual patient’s 
test results in context and provide more valuable           
diagnostic information and advice to patients.   
But Myriad’s patents allow it to deny outside 
access to this “proprietary” information about the 
content of individuals’ DNA.  Kaiser Permanente              
is barred from obtaining full information about its 
own members’ test results.  Instead, Myriad offers 
summaries of these data upon request and only with 
a signed release from a clinician.  Kaiser Permanente 
would compile a database of information learned 
from the test results of its own members — a next-
best alternative to accessing the complete Myriad            
database — but the selective summary data provided 
by Myriad do not enable it to do so. 
Furthermore, if clinicians and researchers outside 
of Myriad were permitted to access and analyze              
the full information in Myriad’s database, they could 
use it to develop a more complete understanding of 
the universe of BRCA1 and BRCA2 mutations and 
variants and the role these genetic factors play in in-
creasing susceptibility to breast and ovarian cancer.  
As just one example, researchers outside Myriad 
could verify whether a particular variant of the 
BRCA genes is actually linked to cancer risk or is          
instead benign.  The consequence of Myriad’s patents 
and the resulting monopoly on BRCA1 and BRCA2 
testing is a broader monopoly on information that         
patients and their physicians may obtain about the 
contents of an individual’s own DNA, including the 
patient’s own heightened risks of life-threatening 
disease. 
Myriad’s patents also have direct negative effects 
on genetic research and understanding.  Myriad 
claims ownership of the BRCA1 and BRCA2 gene          
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sequences, but these genes are a small part of the 
complete human genome.  It is well known that most 
genes do not work alone but rather interact with one 
or more other genes contained in the genome to pro-
duce morphological changes.  A researcher studying 
larger DNA sequences or even the entire genome 
may discover potential effects that implicate the 
BRCA1 and BRCA2 genes but also involve other          
portions of the full genome sequence.  The researcher 
may be compelled to avoid using or disclosing this 
potentially crucial information for fear of treading 
upon Myriad’s intellectual property rights, even if 
the new discovery is not limited to the BRCA1 or 
BRCA2 genes.  See U.S. Dep’t of Health & Human 
Services, Report of the Secretary’s Advisory Comm.           
on Genetics, Health, and Society:  Gene Patents and 
Licensing Practices and Their Impact on Patient        
Access to Genetic Tests 49-62 (Apr. 2010) (describing 
obstacles to whole-genome sequencing presented by 
gene patents), available at http://oba.od.nih.gov/oba/ 
SACGHS/reports/SACGHS_patents_report_2010.pdf.  
This is true not only of the specific genes patented          
by Myriad, but of all patents on isolated human 
DNA.  See id. at 50-52.  The combined effect of these 
patents could lead to fragmented ownership of the 
human genome, with researchers unable to engage in 
meaningful analysis or scientific dialogue for fear of 
violating any number of patents.   
Judge Bryson recognized this problem in his           
opinion dissenting from the court of appeals majority.  
Broadly written patents claiming human genetic          
material may stall genomic research because, “[i]n 
order to sequence an entire genome, a firm would 
have to license thousands of patents from many           
different licensors.  Even if many of those patents            
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include claims that are invalid for anticipation or          
obviousness, the costs involved in determining the 
scope of all of those patents could be prohibitive.”  
Pet. App. 109a (citation omitted). 
II. PATENTS ON ISOLATED DNA INCREASE 
THE COSTS AND REDUCE THE UTILITY 
OF DIAGNOSTIC GENETIC TESTS 
Patents on isolated DNA obstruct the critical            
research that will lead to advances in clinical under-
standing and improvements in future diagnostic             
ability, but more importantly they also prevent pa-
tients from receiving the best diagnostic information 
available now.  In several different ways, the paten-
tee’s monopoly on testing for the DNA sequence in 
question reduces both the quantity and quality of          
information available to patients who need to make 
well-informed decisions about their health and 
health care. 
The Myriad patents at issue in this case have               
already produced such negative effects on patient 
health.  As the district court noted, Myriad has as-
serted its patent rights to prohibit other laboratories 
from offering diagnostic BRCA1 and BRCA2 testing 
using isolated DNA.  See Pet. App. 163a-166a.  
Health care providers like Kaiser Permanente have 
no choice but to rely on Myriad to test patients’ DNA 
samples for mutations to the BRCA1 and BRCA2 
genes.  Since 1997, when the patents-in-suit took          
effect, Kaiser Permanente has ordered BRCA1 and 
BRCA2 testing for its members exclusively through 
Myriad.   
Kaiser Permanente is committed to offering its 
members and patients the best possible medical care; 
when a genetic specialist determines that a test 
should be ordered for a Kaiser Permanente member, 
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it will pay the high rates that Myriad is able to 
charge for its exclusive diagnostic services.  But even 
this is no guarantee that patients will receive the full 
benefit of genetic testing.  A clinician counseling a 
patient at risk for hereditary cancer will want to            
test the family member most likely to have a genetic            
mutation first, in order to identify the specific                
mutation carried in the family and then use a more 
targeted test to analyze the DNA samples of other 
family members (often at one-tenth the cost of the 
comprehensive test).  Thus, the clinician may iden-
tify the patient’s parent, sibling, or other relative              
as the primary candidate for genetic testing.  If the 
patient’s relative is not also a covered Kaiser Perma-
nente member, however, there is no guarantee that 
testing will be feasible.  The cost of each test can            
exceed $3,000.  The relative may have no medical            
insurance, or may have insurance that does not cover 
Myriad’s tests, and the high price tag is often prohi-
bitive.   
In this scenario, Kaiser Permanente still offers 
testing to its member patient, but the test is of            
limited value without a clear, complete picture of the 
familial cancer risk.  For example, consider a Kaiser 
Permanente patient who has no personal history of 
breast cancer and whose individual risk for a BRCA1 
or BRCA2 mutation is comparatively low, but whose 
family history strongly suggests hereditary cancer       
susceptibility.  While testing only the patient herself 
will assist with that patient’s care, the patient is 
likely to produce a negative result because of her low 
individual risk.  This negative result is of limited use 
in isolation.  By contrast, if the family member most 
at risk for a mutation is tested and the mutation is 
found in that family member, other relatives have an 
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incentive to get tested — and those who test negative 
for the same mutation can be certain that they are 
free of the familial risk.   
Kaiser Permanente’s genetics counselors and clini-
cians need access to this kind of complete familial            
information to provide the best advice to patients 
concerning their overall cancer risk, need for surveil-
lance, and candidacy for elective prophylactic sur-
geries, including mastectomies.  The Myriad patents 
and the diagnostic monopoly often make it practical-
ly impossible for Kaiser Permanente to do so. 
If Myriad (or any other entity) did not have patent 
rights to the isolated BRCA1 and BRCA2 genes,            
other facilities would be able to test for mutations in 
those genes.  Having multiple providers may lead to 
competitive pricing; lower costs would mean more 
widespread availability and the ability to obtain a 
“second opinion” by having another facility perform a 
confirmatory test.  Having multiple providers may 
also mean that a wider range of testing options is 
available, rather than the particular tests a monopoly 
provider chooses to offer.  These benefits are possible 
with other diagnostic tests that are not restricted by 
gene patents.  For example, while Myriad offers tests 
screening for colo-rectal cancer, it does not have a        
patent on the affected gene sequences.  Other labora-
tories can therefore offer screening tests, and many 
do so at a lower price than Myriad, to the ultimate 
benefit of patients and consumers as well as public 
and private healthcare payers.   
In fact, but for the Myriad patents, Kaiser Perma-
nente would work to obtain the facilities necessary             
to conduct BRCA1 and BRCA2 screening internally, 
which would dramatically reduce the costs of testing 
and would therefore make it easier to offer screen-         
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ing to the most appropriate candidates, including       
relatives of Kaiser Permanente members who are 
identified as being most at-risk for an inherited gene            
mutation.  In addition, Kaiser Permanente would 
have more control over the testing process and would 
be able to select the most appropriate test for any 
given individual, rather than relying on the set menu 
of choices that Myriad has elected to offer. 
III. PATENTS ON ISOLATED DNA CONFLICT 
WITH PHYSICIANS’ ETHICAL OBLIGA-
TIONS TO PATIENTS
Finally, the patentability of isolated human genes 
can create serious ethical conflicts for physicians.           
Advances in technology are making it possible to          
sequence a patient’s entire genome or exome (the          
active portions of the genome), rather than just test-
ing for variations in the sequence of a particular 
gene.  See Pet. App. 109a.  As discussed above in Part 
I, the issuance of patents on numerous individual 
genes presents serious obstacles to researchers seek-
ing to study the full genome sequence.  These chal-
lenges are even more problematic for laboratories 
and clinicians looking at a patient’s genome or exome 
for diagnostic purposes.  Even if not testing specifi-
cally for variations in a patented gene sequence, such 
as BRCA1 or BRCA2, the clinician may see such a 
variation when analyzing the genome or exome in 
full.  The clinician is then presented with a dilemma:  
whether to disclose the variation to the patient            
and risk violating the patent owner’s intellectual 
property rights, or not disclose that the patient has           
a genetic risk of developing cancer (or any other dis-
ease that may be implicated by gene patents).   
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CONCLUSION 
Because the judgment below raises an important 
issue of patent law with wide-ranging consequences 
to health care providers, certiorari is warranted.  The 
petition for a writ of certiorari should be granted. 
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